GW Pharmaceuticals (GWPH) and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Meeting Highlights Include New Phase 3 Data for EPIDIOLEX in Tuberous Sclerosis…

GW Pharmaceuticals (GWPH) Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019

– Epidiolex U.S. Q2 net sales of $68.4 million – – Positive…

Marijuana Stocks That Have Yet to Reach Their Full Potential 

Marijuana stocks have continuously illustrated their potential for success in the coming…

Marijuana Stocks Just Keep Getting More Enticing

The world of marijuana stocks has remained extremely exciting for quite some…